High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. Issue 1 (2nd January 2018)

• Record Type: Journal Article
• Authors: Si, Ting; Lu, Ying; Li, Fenglin; Jiang, Lei; Pei, Renzhi; Zhou, Jeff X.
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 1(2018)
• Page Start: 114
• Page End: 120
• Publication Date: 2018-01-02
• Subjects: INHBA -- AML -- leukemia -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1324157
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Inhibin-β A (INHBA) is a ligand of the transforming growth factor β superfamily and associated with tumorigenesis and tumor progression in solid tumors. In this study, we investigated the expression levels and clinical significance of INHBA in acute myeloid leukemia (AML). The results showed that high expression of INHBA was significantly correlated with elderly age (>60 years) ( p = .038), adverse cytogenetic risks ( p = .034), negative NPM1 mutation ( p = .016), positive FLT3 internal tandem duplications ( p = .011), and low hemoglobin levels (<60 g/dL) ( p = .04). Patients with high levels of INHBA had poor responses to therapies as indicated by lower complete remission rate ( p = .004), higher early death rate ( p = .018), and shorter relapse-free survival ( p = .04) and overall survival ( p = .003). Moreover, multivariate analysis showed that high expression of INHBA was an independent adverse prognostic factor for AML. Taken together, our study suggested that high expression of INHBA was an adverse prognostic factor for de novo AML.